A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells

Assessing the Expression of A2R Receptors and CD39 and CD73 Ectonucleotidases on Circulating Tumour Cells of Non-small Cell Lung Carcinoma

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05648188

Acronym

LUNGadenosine

Enrollment

Registered

2022-12-13

Start date

2023-01-01

Completion date

2024-10-30

Last updated

2025-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which can be detected before surgery, represent a promising prognostic tool, but the markers characterising their aggressiveness remain to be determined. The NSCLC microenvironment, in which purinergic signalling is a key pathway, controls tumour development. Adenosine derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP, induces immunosuppression of NSCLC by activating A2R receptors. The expression and prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i) compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of patients operated on for early NSCLC, (ii) correlate these data with molecular characteristics and clinical response, (iii) determine on lung cancer lines whether irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute to the identification of new theranostic biomarkers.

Interventions

BIOLOGICALSample

Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

i) Inclusion criteria: * Patient of legal age (\>18 years), any gender, * operated on for stage (IA to IIB) non-small cell lung cancer (NSCLC) ii)

Exclusion criteria

* Patient with any other active cancer. * Lack of evaluable material.

Design outcomes

Primary

Measure	Time frame	Description
Ex vivo expression of A2R (adenosine receptor), CD39, CD73 and P2RX7 on NSCLC and CTC	At inclusion	Presence versus Absence of expression (immunohistochemistry)

Secondary

Measure	Time frame	Description
In vitro impact of radiation therapy on the A2R, CD39, CD73 expression by cells lineage	At inclusion	Upregulation / Downregulation of expression (mRNA by real time PCR)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026